Vagus Nerve Stimulation: Integration of Behavior and Cardiac Modulation (tVNS-MDD)
Primary Purpose
Major Depressive Disorder
Status
Completed
Phase
Not Applicable
Locations
United States
Study Type
Interventional
Intervention
exhalatory-gated transcutaneous vagus nerve stimulation (e-RAVANS)
Inhalatory-gated transcutaneous vagus nerve stimulation (i-RAVANS)
Sponsored by
About this trial
This is an interventional basic science trial for Major Depressive Disorder focused on measuring Transcutaneous vagus nerve stimulation, Stress response circuitry, functional magnetic resonance imaging, respiration, depression
Eligibility Criteria
Inclusion Criteria: Recurrent MDD diagnosis (≥ 2 episodes) with a current active depressive episode.
Exclusion Criteria:
- History of Axis I psychiatric diagnosis other than MDD or anxiety disorder - e.g., substance use disorder, psychotic disorder, or bipolar disorder.
- Current Suicidal Ideation with intent and/or plan or history of suicide attempt within the last year
- Use of psychotropic medications within four weeks prior to study with the exception of Selective Serotonin Reuptake Inhibitors (SSRIs) and Selective Norepinephrine Reuptake Inhibitors (SNRIs) class of antidepressant medication only
- Use of Tricyclic antidepressants (TCAs), Monoamine oxidase inhibitors (MAOIs), and Atypical agents
- History of cardiovascular disease
- History of neuroleptic use
- Past history of substance abuse or dependence within the past 12 months (excludes nicotine)
- Bleeding disorder or use of anticoagulants.
- Pregnancy
- Metallic implants or devices contraindicating magnetic resonance imaging.
- Use of beta blockers
Sites / Locations
- Massachusetts General Hospital
Arms of the Study
Arm 1
Arm 2
Arm Type
Experimental
Active Comparator
Arm Label
Exhalatory-gated tVNS
Inhalatory-gated tVNS
Arm Description
exhalatory-gated tVNS on the left auricle
inhalatory-gated tVNS on the left auricle
Outcomes
Primary Outcome Measures
Brain activity changes [percent blood oxygenation level dependent signal change] evaluated using functional magnetic resonance imaging during a visual stress challenge
Changes in functional magnetic resonance imaging- blood oxygenation level dependent signal (percent signal change) in response to a visual stress challenge compared between exhalatory and inhalatory-gated tVNS
Secondary Outcome Measures
Change in depressive symptoms assessed by the Beck Depression Inventory
Changes from baseline to post-stimulation in the total score of the Beck Depression Inventory compared between exhalatory and inhalatory-gated tVNS. (Beck depression inventory minimum score= 0, maximum score= 63; higher total scores indicate more severe depressive symptoms)
Changes in cardiac autonomic function during functional magnetic resonance imaging
Changes from baseline to post-stimulation in cardiac autonomic function (percent change of High Frequency power index) compared between exhalatory- and inhalatory-gated tVNS.
Full Information
NCT ID
NCT04467164
First Posted
July 1, 2020
Last Updated
July 9, 2020
Sponsor
Massachusetts General Hospital
Collaborators
National Institute of Mental Health (NIMH)
1. Study Identification
Unique Protocol Identification Number
NCT04467164
Brief Title
Vagus Nerve Stimulation: Integration of Behavior and Cardiac Modulation
Acronym
tVNS-MDD
Official Title
Vagus Nerve Stimulation: Integration of Behavior and Cardiac Modulation
Study Type
Interventional
2. Study Status
Record Verification Date
July 2020
Overall Recruitment Status
Completed
Study Start Date
April 15, 2015 (Actual)
Primary Completion Date
September 15, 2018 (Actual)
Study Completion Date
September 22, 2018 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Massachusetts General Hospital
Collaborators
National Institute of Mental Health (NIMH)
4. Oversight
Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
Yes
Data Monitoring Committee
No
5. Study Description
Brief Summary
This study characterized the impact of respiratory-gated transcutaneous vagus nerve stimulation (tVNS) on the modulation of the stress response circuitry, vagal tone and depressed mood in patients with major depressive disorder (MDD). Twenty premenopausal women with recurrent MDD in an active episode were recruited into a single-blind cross-over study that included two functional MRI visits within a one week period with simultaneous mood and physiological assessments. Randomization to exhalatory- or inhalatory-gated tVNS was performed to control for order effects. The study hypothesis was that exhalatory-gated tVNS would have a significantly greater impact on the regulation of brain activity in stress response circuitry, vagal tone and depressed mood in MDD patients compared to inhalation-gated tVNS.
Detailed Description
Major depressive disorder (MDD) has been associated with alterations of the stress response circuitry, including the hypothalamus, amygdala, hippocampus, anterior cingulate cortex, ventromedial, dorsolateral and orbital prefrontal cortices. Many of these regions are morphologically and functionally sexually dimorphic and associated with vulnerability for sex differences in MDD. A major role for the stress response circuitry is to assess potentially stressful stimuli and respond with a neuroendocrine signal that coordinates homeostatic responses throughout the body. Neuroimaging studies have suggested that alterations in this circuitry are implicated in mood dysregulation, increased activation of the hypothalamic-pituitary-adrenal (HPA) axis, and imbalance between the sympathetic and parasympathetic nervous system in depressed persons. Thus, the development of novel interventions that regulate this system may have a significant impact on the improvement of clinical and physiological alterations of MDD.
Vagal nerve stimulation (VNS) is an FDA approved treatment for MDD that modulates circuitry implicated in mood regulation. Recently, a non-invasive variant of VNS, transcutaneous auricular vagus nerve stimulation (tVNS), which targets the auricular branch of the vagus nerve (ABVN) has been proposed. Moreover, previous studies have suggested that the dorsal medullary system receiving vagal afference inputs operates in tune with respiration and that tVNS may be optimized by gating ABVN stimulation to the exhalatory phase of the respiratory cycle. Thus, this study proposed to characterize the impact of respiratory-gated tVNS on the modulation of the stress response circuitry, vagal tone and depressed mood in patients with recurrent major depression (MDD).
Twenty premenopausal women with recurrent MDD in an active episode were recruited into a single-blind cross-over study that included two functional MRI visits, within a one week period, with simultaneous mood and physiological assessments. Randomization to exhalatory- or inhalatory-gated tVNS was performed to control for order effects. Subjects were exposed to a mild visual stress challenge that preceded and followed 30 minutes of exhalatory- or inhalatory-gated tVNS. The study hypothesis was that exhalatory-gated tVNS would have a significantly greater impact on the regulation of brain activity in stress response circuitry, vagal tone and depressed mood in MDD patients compared to inhalation-gated tVNS
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Major Depressive Disorder
Keywords
Transcutaneous vagus nerve stimulation, Stress response circuitry, functional magnetic resonance imaging, respiration, depression
7. Study Design
Primary Purpose
Basic Science
Study Phase
Not Applicable
Interventional Study Model
Crossover Assignment
Masking
Participant
Allocation
Randomized
Enrollment
20 (Actual)
8. Arms, Groups, and Interventions
Arm Title
Exhalatory-gated tVNS
Arm Type
Experimental
Arm Description
exhalatory-gated tVNS on the left auricle
Arm Title
Inhalatory-gated tVNS
Arm Type
Active Comparator
Arm Description
inhalatory-gated tVNS on the left auricle
Intervention Type
Device
Intervention Name(s)
exhalatory-gated transcutaneous vagus nerve stimulation (e-RAVANS)
Other Intervention Name(s)
e-RAVANS
Intervention Description
Non-painful exhalatory-gated electrical stimulation of the auricle for 30 minutes during a functional magnetic resonance imaging session.
Intervention Type
Device
Intervention Name(s)
Inhalatory-gated transcutaneous vagus nerve stimulation (i-RAVANS)
Other Intervention Name(s)
i-RAVANS
Intervention Description
Non-painful inhalatory-gated electrical stimulation of the auricle for 30 minutes during a functional magnetic resonance imaging session.
Primary Outcome Measure Information:
Title
Brain activity changes [percent blood oxygenation level dependent signal change] evaluated using functional magnetic resonance imaging during a visual stress challenge
Description
Changes in functional magnetic resonance imaging- blood oxygenation level dependent signal (percent signal change) in response to a visual stress challenge compared between exhalatory and inhalatory-gated tVNS
Time Frame
1 hour
Secondary Outcome Measure Information:
Title
Change in depressive symptoms assessed by the Beck Depression Inventory
Description
Changes from baseline to post-stimulation in the total score of the Beck Depression Inventory compared between exhalatory and inhalatory-gated tVNS. (Beck depression inventory minimum score= 0, maximum score= 63; higher total scores indicate more severe depressive symptoms)
Time Frame
2 hours
Title
Changes in cardiac autonomic function during functional magnetic resonance imaging
Description
Changes from baseline to post-stimulation in cardiac autonomic function (percent change of High Frequency power index) compared between exhalatory- and inhalatory-gated tVNS.
Time Frame
1 hour
10. Eligibility
Sex
Female
Gender Based
Yes
Gender Eligibility Description
premenopausal women only
Minimum Age & Unit of Time
25 Years
Maximum Age & Unit of Time
40 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Recurrent MDD diagnosis (≥ 2 episodes) with a current active depressive episode.
Exclusion Criteria:
History of Axis I psychiatric diagnosis other than MDD or anxiety disorder - e.g., substance use disorder, psychotic disorder, or bipolar disorder.
Current Suicidal Ideation with intent and/or plan or history of suicide attempt within the last year
Use of psychotropic medications within four weeks prior to study with the exception of Selective Serotonin Reuptake Inhibitors (SSRIs) and Selective Norepinephrine Reuptake Inhibitors (SNRIs) class of antidepressant medication only
Use of Tricyclic antidepressants (TCAs), Monoamine oxidase inhibitors (MAOIs), and Atypical agents
History of cardiovascular disease
History of neuroleptic use
Past history of substance abuse or dependence within the past 12 months (excludes nicotine)
Bleeding disorder or use of anticoagulants.
Pregnancy
Metallic implants or devices contraindicating magnetic resonance imaging.
Use of beta blockers
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Jill M Goldstein, PhD
Organizational Affiliation
Massachusetts General Hospital
Official's Role
Principal Investigator
Facility Information:
Facility Name
Massachusetts General Hospital
City
Boston
State/Province
Massachusetts
ZIP/Postal Code
02114
Country
United States
12. IPD Sharing Statement
Plan to Share IPD
No
Learn more about this trial
Vagus Nerve Stimulation: Integration of Behavior and Cardiac Modulation
We'll reach out to this number within 24 hrs